Charles River Laboratories Intl. Inc vs Tyson Foods, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Tyson Foods, Inc. trades at $53.43 (market cap $18.41B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Tyson Foods, Inc. for 76 Days on average.
| CRL | TSN | |
|---|---|---|
Market Cap | $14.23B | $18.41B |
Volume | 1,176,885 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $310.77 | $68.75 |
52-Week Low | $149.93 | $50.47 |
Typical Hold Time | 33 Days | 76 Days |
Enterprise Value | $17.06B | $25.68B |
Dividend Yield | — | 3.9% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
Tyson Foods (TSN) trades at $52.34, up 1.24% on the day, with a bullish technical signal but mixed earnings history including a recent Q4 2025 miss. Valuation ratios like P/S of 0.33 appear attractive, but thin net margins of 1.03% and ongoing cash flow challenges highlight operational pressures. Recent news includes a lowered fiscal 2026 outlook and a securities investigation, adding uncertainty despite insider buying and institutional interest.
The stock offers a potential 25% upside to the consensus price target of $65.40, supported by a majority analyst buy rating. However, risks are elevated from beef segment losses, negative cash flows, and legal scrutiny. Investor sentiment is cautious amid guidance cuts, making earnings execution critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →